STOCKS TELEGRAPH

Tag: SPRB

  • Spruce Biosciences Inc. (SPRB) stock Continues Bearish Momentum After Hours

    Spruce Biosciences Inc. (SPRB) stock lost a further 6.48% in the after-hours at $3.8999 on December 21. During regular trading, the stock fluctuated between a high of $4.6400 and a low of $3.8800 at 9.09M shares. SPRB closed the session with a loss of 2.34% at its closing value of $4.1700.

    The continued downtrend in the stock can be subjected to profit booking and corrections due to its previous gains.

    Currently, the 23.46 million outstanding shares of the company trade at a market capitalization of $100.19 million.

    SPRB’s Movements

    On Friday, December 17, Oppenheimer declared a positive outperform rating to the SPRB stock. Moreover, the stock also received a price target of $15 while SPRB saw a hammer chart pattern the day before. Consequently, SPRB made huge gains in Friday’s session. SPRB reached a high of $5.80 on Friday, reaching the price after 70 days. This marked a big gain in the stock’s recent timeline. Resultantly, the stock entered corrections in the following aftermarket and premarket sessions. While it did see some more gains on Monday, it fell once again to shed its gains to profit booking. Hence, the stock seems to continue losing due to profit booking from its gains.

    In the past five days, the stock has gained 71.60% and over 57.3% last month. Moreover, SPRB has subtracted a value of 36.34% in the past three months. In addition, the year-to-date loss for the stock stands at 82.85%.

    Corporate Updates

    On November 15, the company announced its corporate updates for the third quarter of 2021. According to the third quarter:

    • SPRB expects to report topline data from CAHmelia-203 in 2023 due to the impacts of Covid-19 on patient enrollment and site activation.
    • SPRB expanded the phase 2 CAHmelia program in Adult Classic CAH to Australia and Canada.
    • The phase 2 clinical trial in Pediatric Classic CAH initiation plan is on track.
    • The Phase 2 Proof of Concept clinical trial in PCOS initiation plan is also on track.

    SPRB’s Financial Results

    Alongside the corporate updates, SPRB also announced its third-quarter financial results for the third quarter of 2021. In the Q3 of 2021, the R&D and G&A expenses were $8.6 million and $2.8 million, respectively.

    Moreover, SPRB incurred a net loss of $11.4 million in the third quarter of 2021, against $9.6 million in Q3 of 2020.

    In addition, the company ended the quarter with cash, equivalents, and investments of $131.3 million.

  • Spruce Biosciences Inc. (SPRB) stock’s Upsurge After Hours. Here’s what’s happening?

    Spruce Biosciences Inc. (SPRB) stock gained 29.84% in the after-hours at $3.22 on December 16. With no recent news from the company, both fundamental and technical aspects seem to be driving the stock up.

    In regular trading, the stock lost 0.80% at 6.91 million shares, as the stock closed at $2.48 on Thursday. Soon in the aftermarket session, the stock saw reversal as it gained big on a heft volume of 6.64 million shares.

    The clinical-stage biopharmaceutical company has a market capitalization of $58.88 million. Currently, the company has 23.46 million shares outstanding in the market.

    SPRB stock’s Movement

    In the past five days, the stock has lost 3.13% and 15.65% last month. Moreover, the three-month loss for the stock stands at 67.79% and 89.80% year to date.

    While no apparent recent news is causing the stock’s recent move into the green, technicals, and fundamentals seem responsible. In the previous trading session, a hammer chart pattern was formed. The bulls were able to counteract the bears and hence the trend was reversed. Moreover, it seems as the optimism for the future earnings of the company is also rising. In the past 30 days, the current year’s estimated consensus EPS has increased by 8.1%.

    Consequently, SPRB stock entered green in the after-hours on Thursday at a heavy volume. While the stock did gain big, there is a possibility of it falling under corrections soon.

    Recent Developments

    Recently, the company participated in the Piper Sandler 33rd Annual Virtual Healthcare Conference. The conference was held from November 29, 2021, to December 2, 2021. Further, SPRB’s Chief Financial Officer, Samir Gharib presented at the conference.

    Previously, the company announced a new appointment within the company, on November 15. Mike Grey was appointed as the interim Chief Executive Officer. Currently, Mr. Grey is serving as the Executive Chairman of the Spruce Board. Furthermore, he will succeed Richard King, who will remain as a strategic advisor till December 31, 2021.

    Moreover, the company is in search of a permanent Chief Executive Chief Officer.

    SPRB’s Financials

    On November 15, SPRB declared its financial results for the third quarter of 2021. In the third quarter of 2021, the company incurred a net loss of $11.4 million against $9.6 million in the Q3 of 2020.

    Moreover, the company ended the quarter with cash, cash equivalents, and investments of $131.3 million.